CTS 2190
Alternative Names: CTS-2190Latest Information Update: 03 Jul 2025
At a glance
- Originator CytosinLab Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein-arginine N-methyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from a phase I/II trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 25 Apr 2025 Pharmacodynamics data from a phase I/II trial in Solid tumours released by CytosinLab Therapeutics
- 13 Sep 2024 Efficacy, adverse events, pharmacokinetics and pharmacodynamics data from a phase I/II trial in Solid tumours presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)